Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Am J Physiol Heart Circ Physiol ; 311(6): H1431-H1436, 2016 12 01.
Article in English | MEDLINE | ID: mdl-27765750

ABSTRACT

Oxidative stress is a key driver of vascular dysfunction in diabetes mellitus. Ebselen is a glutathione peroxidase mimetic. A single-site, randomized, double-masked, placebo-controlled, crossover trial was carried out in 26 patients with type 1 or type 2 diabetes to evaluate effects of high-dose ebselen (150 mg po twice daily) administration on oxidative stress and endothelium-dependent vasodilation. Treatment periods were in random order of 4 wk duration, with a 4-wk washout between treatments. Measures of oxidative stress included nitrotyrosine, plasma 8-isoprostanes, and the ratio of reduced to oxidized glutathione. Vascular ultrasound of the brachial artery and plethysmographic measurement of blood flow were used to assess flow-mediated and methacholine-induced endothelium-dependent vasodilation of conduit and resistance vessels, respectively. Ebselen administration did not affect parameters of oxidative stress or conduit artery or forearm arteriolar vascular function compared with placebo treatment. There was no difference in outcome by diabetes type. Ebselen, at the dose and duration evaluated, does not improve the oxidative stress profile, nor does it affect endothelium-dependent vasodilation in patients with diabetes mellitus.


Subject(s)
Antioxidants/pharmacology , Azoles/pharmacology , Brachial Artery/drug effects , Diabetes Mellitus/physiopathology , Endothelium, Vascular/drug effects , Organoselenium Compounds/pharmacology , Oxidative Stress/drug effects , Vasodilation/drug effects , Adult , Brachial Artery/diagnostic imaging , Brachial Artery/physiopathology , Case-Control Studies , Cross-Over Studies , Diabetes Mellitus/metabolism , Dinoprost/analogs & derivatives , Dinoprost/metabolism , Double-Blind Method , Endothelium, Vascular/physiopathology , Female , Forearm/blood supply , Glutathione/drug effects , Glutathione/metabolism , Humans , Isoindoles , Male , Methacholine Chloride/pharmacology , Middle Aged , Parasympathomimetics/pharmacology , Plethysmography , Tyrosine/analogs & derivatives , Tyrosine/drug effects , Tyrosine/metabolism , Ultrasonography
2.
Circulation ; 109(7): 898-903, 2004 Feb 24.
Article in English | MEDLINE | ID: mdl-14757696

ABSTRACT

BACKGROUND: Free radical injury contributes to cardiac dysfunction during ischemia-reperfusion. Detoxification of free radicals requires maintenance of reduced glutathione (GSH) by NADPH. The principal mechanism responsible for generating NADPH and maintaining GSH during periods of myocardial ischemia-reperfusion remains unknown. Glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway, generates NADPH in a reaction linked to the de novo production of ribose. We therefore hypothesized that G6PD is essential for maintaining GSH levels and protecting the heart during ischemia-reperfusion injury. METHODS AND RESULTS: Susceptibility to myocardial ischemia-reperfusion injury was determined in Langendorff-perfused hearts isolated from wild-type mice (WT) and mice lacking G6PD (G6PD(def)) (20% of WT myocardial G6PD activity). During global zero-flow ischemia, cardiac function was similar between WT and G6PD(def) hearts. On reperfusion, however, cardiac relaxation and contractile performance were greatly impaired in G6PD(def) myocardium, as demonstrated by elevated end-diastolic pressures and decreased percent recovery of developed pressure relative to WT hearts. Contractile dysfunction in G6PD(def) hearts was associated with depletion of total glutathione stores and impaired generation of GSH from its oxidized form. Increased ischemia-reperfusion injury in G6PD(def) hearts was reversed by treatment with the antioxidant MnTMPyP but unaffected by supplementation of ribose stores. CONCLUSIONS: These results demonstrate that G6PD is an essential myocardial antioxidant enzyme, required for maintaining cellular glutathione levels and protecting against oxidative stress-induced cardiac dysfunction during ischemia-reperfusion.


Subject(s)
Glucosephosphate Dehydrogenase Deficiency/complications , Glucosephosphate Dehydrogenase/physiology , Myocardial Contraction/physiology , Myocardial Ischemia/genetics , Myocardial Reperfusion Injury/genetics , Animals , Antioxidants/pharmacology , Antioxidants/therapeutic use , Female , Genotype , Glucosephosphate Dehydrogenase/genetics , Glutathione/metabolism , Male , Metalloporphyrins/pharmacology , Metalloporphyrins/therapeutic use , Mice , Mice, Knockout , Myocardial Contraction/drug effects , Myocardial Ischemia/enzymology , Myocardial Ischemia/physiopathology , Myocardial Reperfusion Injury/enzymology , Myocardial Reperfusion Injury/physiopathology , NADP/physiology , Oxidation-Reduction , Ribose/deficiency , Ribose/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL